Skip to main content

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

To learn more about Triangle CERSI, join our mailing list for future communications.

Triangle 008: Educational Resources to Support FDA's Patient‐Focused Drug Development Guidance Series (PARCR)

Research

Educational Resources to Support FDA's Patient‐Focused Drug Development Guidance Series (PARCR Project)

CERSI P.I. and Collaborators

Kevin Weinfurt, PhD (Duke University)

PARCR Advisory Board

 

CERSI Subcontractors

R.J. Wirth, Vector Psychometric Group

Jerry Gschwind, Symphony Learning Partners

 

FDA SME

Robyn Bent, RN, MS

Patient-focused Approaches to Rigorous Clinical Research (PARCR)

The FDA’s Patient-Focused Drug Development (PFDD) guidance series was developed to address, in a stepwise manner, how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers for medical product development and regulatory decision-making. 

These guidance documents discuss scientific topics and methods that may not be well understood by all users. Therefore, this project will develop educational materials to help users better understand and incorporate the recommendations and advice presented in the guidance series.

Project Description and Goals

The PARCR project has 4 goals. Goal 1 of this project is to develop education modules that explain the Roadmap to Patient-Focused Outcome Measurement in Clinical Trials and how the four PFDD guidance documents inform each stage. Goal 2 is to create modules that discuss approaches for identifying, modifying, or developing measures of how patients feel or function for use in clinical trials. These measures are called Clinical Outcome Assessments (COAs). Goal 3 is to develop modules that discuss how to use COAs in clinical trials to understand the effects of medical products on people’s health. Goal 4 is to develop training materials on special topics in patient-focused outcome measurement, including considerations for use in pediatric patients, populations affected by rare diseases, and/or conditions where patients cannot reliably self-report.

Anticipated Outcomes of Interest

The PARCR  project will produce training materials on the PFDD guidance series for FDA staff and training materials on the PFDD guidance series for external stakeholders, including regulated industries, academic researchers, and patient‐powered research groups. Additional outcomes may include presentations internally at FDA or externally to raise awareness about the educational materials.

 

Publications

  1. Weinfurt KP, Wirth RJ, Edwards MC, Reeve BB. Applying the Argument-Based Approach to Validation With Clinical Outcome Assessments: Strategies for Constructing a Rationale. Value in Health. 2026.

FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making

PARCR Project Website

How does this project fit into the FDA's Regulatory Science Framework?

This project will modernize development and evaluation of FDA-regulated products and invigorate public health preparedness and response of FDA, patients and consumers.

Want to learn more about Triangle CERSI?

Reach out to us through our Contact page to learn more about Triangle CERSI.